Navigation Links
ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
Date:10/17/2011

treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors.  Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, CCX282-B (Traficet-EN, now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. ChemoCentryx's lead independent drug candidate, CCX140-B, a CCR2 antagonist, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetes. CCX140-B is expected to enter Phase II clinical development for the treatment of diabetic nephropathy in 2011. Other clinical programs include CCX354, a CCR1 antagonist which recently completed a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, in Phase II clinical development for the treatment of vasculitis; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoCentryx also has several programs in advanced preclinical development.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy o
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3,  2015 About ... bio-artificial devices, which are implanted or integrated ... organs. These include artificial heart, kidney, pancreas, ... polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ... artificial organs. These organs are incorporated with ...
(Date:9/3/2015)... 3, 2015 About dry eye syndrome Dry ... to deficient tear production or quick tear evaporation or ... types: aqueous tear deficient dry eye and evaporative dry ... do not produce enough tears, whereas meibomian gland dysfunction ... to slow tear evaporation and maintain tear stability. The ...
(Date:9/3/2015)... Sept. 3, 2015  Ascendis Pharma A/S ... biotechnology company that applies its innovative TransCon ... today announced plans to present at several ... Healthcare Conference in BostonDate: , Thursday, September ... of America Merrill Lynch Global Healthcare Conference ...
Breaking Medicine Technology:Global Artificial Organ Market 2015-2019 2Global Dry Eye Syndrome Market 2015-2019 2Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
... WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today ... on the Company's prostate cancer drug candidate CB7630,(abiraterone ... Annual Meeting, which is currently taking place,in Anaheim, ... A.,Yap from the Cancer Research UK Centre for ...
... 40/12.5 and 40/25 mg/day and Amlodipine +,Benazepril ... Society of,Hypertension Twenty-Second Annual Scientific Meeting, PARSIPPANY, ... data,presented today at the American Society of ... Chicago,demonstrated that the fixed-dose combination Benicar HCT,(olmesartan ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Keeping mold ... and around the home is quite common. Mold can grow anywhere - on carpet, ... leaking pipes. Checking for excessive moisture and water in the home is key to ...
(Date:9/4/2015)... PA (PRWEB) , ... September 04, 2015 , ... Many consumers are looking for a ... could be their solution. , The patent-pending K Med Cups provide a quick and simple ... help to relieve a cold, flu or cough. As a result, they enhance comfort and ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... comparison to settlements under the Stark physician self-referral law. “Stark Law DOs ... webinar from Atlantic Information Services, Inc. (AIS), will detail which deals are attracting ...
(Date:9/4/2015)... ... , ... Friday night, Chicago lovebirds Jenny McCarthy and Donnie Wahlberg celebrated their ... supporting families affected by autism, raising nearly $250,000. , 150 guests, including event ... Oscar Swan Inn to support the cause. , McCarthy tugged the heartstrings of ...
Breaking Medicine News(10 mins):Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
... Sacramento - On Tuesday, April 28, at 1:30 p.m., Donate, ... Padilla,s legislation Senate Bill 552 requiring ... classes to include 15 minutes of education regarding, ... would provide California students with the basic knowledge ...
... A defining hallmark of Alzheimer,s disease is the accumulation ... "senile plaques," in the brain,s cortex and hippocampus, where ... California, San Diego School of Medicine have identified a ... increase in the generation of Aβ. Their findings, ...
... 2009 GuidanceBETHESDA, Md., April 27 Hanger Orthopedic Group, Inc. ... million for the quarter ended March 31, 2009, an increase ... prior year. Net income increased $0.9 million, or 26.6%, ... $3.6 million last year. Net income applicable to common ...
... Health Association (APHA) urges the public to use the current ... and their families are prepared for potential pandemics, disasters or ... too early to know the degree to which the current ... the speed with which the virus has spread around the ...
... Preparedness Manual," a complimentary resource that can assist in planning for, ... ... Houston, TX (PRWEB) April 27, 2009 -- With more than ... the recent swine influenza outbreak has triggered global concern as governments ...
... computers, pharmacists for proper prescribing , , MONDAY, April 27 ... cost lives and dollars each year in the United ... pharmacists can work to reduce these mistakes. , Medication ... affecting at least 1.5 million people every year and ...
Cached Medicine News:Health News:Donate Life California to Hold Press Conference on Organ Donation Education, April 28, 1:30 p.m., on State Capitol West Steps 2Health News:Novel role of protein in generating amyloid-beta peptide 2Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 2Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 3Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 4Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 5Health News:Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009 6Health News:Swine Flu Reinforces the Importance of Preparing for Emergencies, Says APHA 2Health News:'Pandemic Preparedness Manual' Offers Guide to Dealing with Possible Swine Flu Pandemic 2Health News:'Pandemic Preparedness Manual' Offers Guide to Dealing with Possible Swine Flu Pandemic 3Health News:Medication Errors Could Be Cut: Experts 2Health News:Medication Errors Could Be Cut: Experts 3Health News:Medication Errors Could Be Cut: Experts 4
Revised Drug calibrator that replaces existing Drug calibrator - this product contains Lithium in addition to Digoxin, Phenobarbital, OPhenytoin, & Theophulline....
For the qualitative and semi-quantitative measurement of RF in human serum....
... The BD Macro-Vue RPR (Rapid ... and Tear-drop Tests are nontreponemal testing ... syphilis described in A Manual of ... in this manual are the most ...
... The BD Macro-Vue RPR (Rapid Plasma ... Tear-drop Tests are nontreponemal testing procedures ... described in A Manual of Tests ... this manual are the most widely ...
Medicine Products: